Accelerate Diagnostics Inc AXDX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:25 PM EDT
0.98quote price arrow up+0.0552 (+5.9689%)
Volume
106
Close
0.9248quote price arrow down-0.0171 (-1.8155%)
Volume
26,771
52 week range
0.73 - 11.90
Loading...
  • Open0.9199
  • Day High0.98
  • Day Low0.9199
  • Prev Close0.9419
  • 52 Week High11.90
  • 52 Week High Date06/12/23
  • 52 Week Low0.73
  • 52 Week Low Date04/18/24

Key Stats

  • Market Cap20.035M
  • Shares Out21.66M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta0.56
  • YTD % Change-76.41

KEY STATS

  • Open0.9199
  • Day High0.98
  • Day Low0.9199
  • Prev Close0.9419
  • 52 Week High11.90
  • 52 Week High Date06/12/23
  • 52 Week Low0.73
  • 52 Week Low Date04/18/24
  • Market Cap20.035M
  • Shares Out21.66M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta0.56
  • YTD % Change-76.41

RATIOS/PROFITABILITY

  • EPS (TTM)-5.50
  • P/E (TTM)-0.17
  • Fwd P/E (NTM)-0.40
  • EBITDA (TTM)-49.589M
  • ROE (TTM)-837.84%
  • Revenue (TTM)12.059M
  • Gross Margin (TTM)30.96%
  • Net Margin (TTM)-510.97%
  • Debt To Equity (MRQ)-189.43%

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Accelerate Diagnostics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation...
Hany Massarany
Independent Chairman of the Board
John Phillips
President, Chief Executive Officer, Director
David Patience
Chief Financial Officer
Lawrence Mertz Ph.D.
Chief Technology Officer
Address
SUITE 108, 303 E 17TH AVE
Denver, CO
80203
United States

Top Peers

SYMBOLLASTCHG%CHG
NEPH
Nephros Inc
2.20-0.13-5.58%
VVOS
Vivos Therapeutics Inc
2.63UNCHUNCH
ULGX
21st North Inc
0.0001UNCHUNCH
THMO
Thermogenesis Holdings Inc
0.70+0.0089+1.2877%
TTOO
T2 Biosystems Inc
3.72+0.07+1.92%